Major League Baseball made a major change to its drug-testing policy in December, removing cannabis from its list of Banned Substances. The league now plans to treat weed like alcohol, offering players optional treatment.
That’s a major change in how most professional sports league’s treats cannabis, which many athletes have turned to for training and recovery.
Also, in the wake of the overdose death of a pitcher — the Los Angeles Angels’ Tyler Skaggs — the league has focused on testing for opioid misuse. The policy amendments also provide players treatment when they test positive for substances on the Drugs of Abuse list, which now includes opioids, cocaine, LSD and MDMA, among other drugs.
The Trump administration has supposedly assembled a team of federal agency leaders for the purpose of promoting negative views on U.S. cannabis legalization. Cannabis industry members and advocates say the effort would be deeply misguided, and ultimately too late.
On Wednesday, BuzzFeed News reported that the White House has “secretly amassed” a committee of federal agencies meant to “combat public support for marijuana and cast state legalization measures in a negative light” while also “attempting to portray the drug as a national threat,” based on interviews and documents acquired by BuzzFeed.
The benefits of medicinal marijuana have been extolled by United States residents for a while, and now it’s Australia’s turn.
After passing legislation in February, this Sunday saw the Narcotic Drugs Amendment Bill 2016 come into being. This means people or organisations in Australia are now able to apply for a license to cultivate and manufacture medical cannabis in Australia.
How does one apply? (We hear you asking.) Well don’t get too excited, recreational weed-smokers. The Office of Drug Control will accept applications for cannabis cultivation from people deemed “fit and proper.”
Interested people and businesses will have to pass a security test set by the office, and show the proposed location they’d be growing medicinal marijuana in, to ensure it’s not shady (metaphorically, and perhaps literally).
Compared to currently approved drugs prescribed for the treatment of Alzheimer’s disease, THC is a considerably superior inhibitor of Abeta aggregation, and this study provides a previously unrecognized molecular mechanism through which cannabinoid molecules may directly impact the progression of this debilitating disease.